Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07209326 · 1 trial · 2 indications
blood pressure, pulse rate, temperature, respiration rate
| Arm | Type | Description |
|---|---|---|
| Treatment Healthy Participants | EXPERIMENTAL | Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326 |
| Placebo Healthy Participants | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Treatment for SCD | EXPERIMENTAL | Participants will receive a multiple dose of subcutaneous PF-07209326 |
| Name | Type | Description |
|---|---|---|
| Placebo | BIOLOGICAL | Participants will receive matching placebo |
| PF-07209326 | BIOLOGICAL | Participants will receive SC or IV single ascending doses |
Inclusion Criteria Health Participants: 1\. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). Exclusion Criteria Healthy Participants: 1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, immunocomprom...
PF-07209326 is an investigational monoclonal antibody developed by Pfizer, Inc. (NYSE: PFE) for sickle cell anemia, a hematologic disorder. It is in Phase 1 clinical development and has been studied in a single completed trial. It is not yet approved for any indication.
PF-07209326 is being developed as a potential treatment for sickle cell anemia. It has been evaluated in a Phase 1 dose escalation study that enrolled healthy participants and participants with sickle cell disease. The drug remains investigational and is not approved for use in sickle cell anemia or any other condition.
PF-07209326 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating this monoclonal antibody in sickle cell anemia and in healthy volunteers.
PF-07209326 is in Phase 1 clinical development. The only listed trial is a completed Phase 1 dose escalation study. The drug is investigational and has not received FDA approval for any indication.
PF-07209326 has been studied in one clinical trial, NCT04255875, titled Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease. This Phase 1 trial was completed, enrolled 52 participants, was randomized, double-blind, and placebo-controlled, and was conducted in the United States.